Study of Methylprednisolone with JAK Inhibitors Abrocitinib or Tofacitinib for Treating Toxic Epidermal Necrolysis

What this Trial Is About

Researchers are evaluating the effectiveness and safety of combining methylprednisolone with two different JAK inhibitors, abrocitinib and tofacitinib, in treating toxic epidermal necrolysis TEN. This early phase 1 study aims to compare these combinations to understand their impact on this severe skin condition. The study is open-label, non-randomized, and conducted at a single center. Participants receive methylprednisolone at a dose of 1 mgkg of body weight per day combined with either abrocitinib 200 mg daily or tofacitinib 10 mg daily. Both treatments are given for a duration of two weeks. The study has two treatment arms, one for each JAK inhibitor, to assess their efficacy and safety when combined with methylprednisolone. During the study, researchers will monitor the time it takes for skin healing reepithelization over up to eight weeks. They will also observe any adverse events for up to twelve weeks. Participants will undergo regular follow-up visits and assessments, including monitoring blood parameters, liver and kidney function, to evaluate treatment effects and safety. The total participation duration varies depending on individual follow-up schedules.

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis